Acute-Onset Pneumonitis while Administering the First Dose of Durvalumab

In locally advanced non-small cell lung cancer (NSCLC) patients, consolidation therapy with durvalumab (an anti-PD-L1 monoclonal antibody) has proven to significantly increase both progression free and overall survival after chemoradiotherapy. Here, we describe a case of acute pneumonitis during dur...

Descripción completa

Detalles Bibliográficos
Autores principales: Tonk, Erwin H.J., van Lindert, Anne S.R., Verhoeff, Joost J.C., Suijkerbuijk, Karijn P.M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6738224/
https://www.ncbi.nlm.nih.gov/pubmed/31543778
http://dx.doi.org/10.1159/000502202
_version_ 1783450798609399808
author Tonk, Erwin H.J.
van Lindert, Anne S.R.
Verhoeff, Joost J.C.
Suijkerbuijk, Karijn P.M.
author_facet Tonk, Erwin H.J.
van Lindert, Anne S.R.
Verhoeff, Joost J.C.
Suijkerbuijk, Karijn P.M.
author_sort Tonk, Erwin H.J.
collection PubMed
description In locally advanced non-small cell lung cancer (NSCLC) patients, consolidation therapy with durvalumab (an anti-PD-L1 monoclonal antibody) has proven to significantly increase both progression free and overall survival after chemoradiotherapy. Here, we describe a case of acute pneumonitis during durvalumab administration for locally advanced NSCLC, causing persistent symptomatology and steroid treatment to date. To our knowledge, acute-onset pneumonitis during infusion of a PD-L1 inhibitor has not been described previously. This case illustrates that ICI-induced pneumonitis can occur anytime during treatment, especially after chemoradiation.
format Online
Article
Text
id pubmed-6738224
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-67382242019-09-22 Acute-Onset Pneumonitis while Administering the First Dose of Durvalumab Tonk, Erwin H.J. van Lindert, Anne S.R. Verhoeff, Joost J.C. Suijkerbuijk, Karijn P.M. Case Rep Oncol Case Report In locally advanced non-small cell lung cancer (NSCLC) patients, consolidation therapy with durvalumab (an anti-PD-L1 monoclonal antibody) has proven to significantly increase both progression free and overall survival after chemoradiotherapy. Here, we describe a case of acute pneumonitis during durvalumab administration for locally advanced NSCLC, causing persistent symptomatology and steroid treatment to date. To our knowledge, acute-onset pneumonitis during infusion of a PD-L1 inhibitor has not been described previously. This case illustrates that ICI-induced pneumonitis can occur anytime during treatment, especially after chemoradiation. S. Karger AG 2019-08-06 /pmc/articles/PMC6738224/ /pubmed/31543778 http://dx.doi.org/10.1159/000502202 Text en Copyright © 2019 by S. Karger AG, Basel http://creativecommons.org/licenses/by-nc/4.0/ This article is licensed under the Creative Commons Attribution-NonCommercial-4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission.
spellingShingle Case Report
Tonk, Erwin H.J.
van Lindert, Anne S.R.
Verhoeff, Joost J.C.
Suijkerbuijk, Karijn P.M.
Acute-Onset Pneumonitis while Administering the First Dose of Durvalumab
title Acute-Onset Pneumonitis while Administering the First Dose of Durvalumab
title_full Acute-Onset Pneumonitis while Administering the First Dose of Durvalumab
title_fullStr Acute-Onset Pneumonitis while Administering the First Dose of Durvalumab
title_full_unstemmed Acute-Onset Pneumonitis while Administering the First Dose of Durvalumab
title_short Acute-Onset Pneumonitis while Administering the First Dose of Durvalumab
title_sort acute-onset pneumonitis while administering the first dose of durvalumab
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6738224/
https://www.ncbi.nlm.nih.gov/pubmed/31543778
http://dx.doi.org/10.1159/000502202
work_keys_str_mv AT tonkerwinhj acuteonsetpneumonitiswhileadministeringthefirstdoseofdurvalumab
AT vanlindertannesr acuteonsetpneumonitiswhileadministeringthefirstdoseofdurvalumab
AT verhoeffjoostjc acuteonsetpneumonitiswhileadministeringthefirstdoseofdurvalumab
AT suijkerbuijkkarijnpm acuteonsetpneumonitiswhileadministeringthefirstdoseofdurvalumab

Ejemplares similares